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25-hydroxycholesterol contributes to cerebral
inﬂammation of X-linked adrenoleukodystrophy
through activation of the NLRP3 inﬂammasome
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Eunju Lee2, Wonsuk Yang1, Hoon-Chul Kang4, Sung Won Kwon3, Je-Wook Yu2,** & Dong-Wook Kim1,**
X-linked adrenoleukodystrophy (X-ALD), caused by an ABCD1 mutation, is a progressive
neurodegenerative disorder associated with the accumulation of very long-chain fatty acids
(VLCFA). Cerebral inﬂammatory demyelination is the major feature of childhood cerebral
ALD (CCALD), the most severe form of ALD, but its underlying mechanism remains poorly
understood. Here, we identify the aberrant production of cholesterol 25-hydroxylase (CH25H)
and 25-hydroxycholesterol (25-HC) in the cellular context of CCALD based on the analysis of
ALD patient-derived induced pluripotent stem cells and ex vivo ﬁbroblasts. Intriguingly,
25-HC, but not VLCFA, promotes robust NLRP3 inﬂammasome assembly and activation via
potassium efﬂux-, mitochondrial reactive oxygen species (ROS)- and liver X receptor
(LXR)-mediated pathways. Furthermore, stereotaxic injection of 25-HC into the corpus
callosum of mouse brains induces microglial recruitment, interleukin-1b production, and
oligodendrocyte cell death in an NLRP3 inﬂammasome-dependent manner. Collectively, our
results indicate that 25-HC mediates the neuroinﬂammation of X-ALD via activation of the
NLRP3 inﬂammasome.
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X
-linked adrenoleukodystrophy (X-ALD) is an inherited
metabolic disorder caused by a loss of function mutation
in the ATP-binding cassette transporter subfamily D
member 1 (ABCD1) gene1. ABCD1 mediates the transport of
saturated very long-chain fatty acids (VLCFA) from the cytosol
to the peroxisome for degradation2. Dysfunctional ABCD1,
therefore, leads to the accumulation of VLCFA particularly in
the adrenal cortex, central nervous system and plasma as well3,4.
While abnormal accumulation of VLCFA is considered an
important marker for X-ALD5,6, how VLCFA is involved in the
pathogenesis of X-ALD remains to be clariﬁed. The main
manifestation of X-ALD is milder axonopathy of the spinal
cord and more severe cerebral inﬂammatory demyelination7.
The most severe phenotype of X-ALD is childhood cerebral ALD
(CCALD), which is accompanied by acute inﬂammatory
demyelination of the central nervous system that leads to a
vegetative state or death within 3–5 years of onset8. On the other
hand, adrenomyeloneuropathy (AMN), the most prevalent
phenotype, manifests as a slowly progressive myelopathy in the
adulthood7,9.
The presence of cerebral inﬂammation is a signiﬁcant
symptom of CCALD, but how cerebral inﬂammation is initiated
or promoted in CCALD patients is still poorly understood.
Nevertheless, abnormal accumulation of VLCFA is considered as
a biochemical trigger for the pathophysiology of CCALD
including cerebral inﬂammatory response10. Furthermore, the
pathogenesis of cerebral ALD could be affected by a range of
genetic and environmental factors9. Although Abcd1-deﬁcient
mice exhibited an increased level of VLCFA in the brain and
adrenal gland, these mice did not show any characteristics of
CCALD phenotypes including the cerebral pathology11. Thus,
this lack of CCALD phenotype in Abcd1-deﬁcient mice makes
it more difﬁcult to study the molecular basis of cerebral
inﬂammation of CCALD caused by VLCFA accumulation.
A dysregulated innate immune response has been increasingly
considered a potential contributor to cerebral inﬂammation and
neurodegenerative disorders12. Of particular interest, nucleotide-
binding oligomerization domain-like (NOD-like) receptor
containing pyrin domain 3 (NLRP3) inﬂammasome signalling
has been proposed as a crucial mediator in the progression of
Alzheimer’s diseases13,14. The inﬂammasome is a caspase-1-
activating multi-protein complex that, once assembled, leads to
the production of key pro-inﬂammatory cytokines interleukin-1b
(IL-1b) and IL-18 (ref. 15). Unlike the other identiﬁed
inﬂammasomes, NLRP3 can be activated by a wide range of
stimulators from microbial toxin to host endogenous metabolites
such as palmitate, cholesterol crystals and amyloid b (refs 15,16).
On the basis of its potent recognition capability under diverse
stress conditions, NLRP3 is thought to be a crucial sensor of
cellular abnormalities to initiate inﬂammation. The robust
expression of the NLRP3 inﬂammasome components in
mouse brain microglia was reported previously17. Of particular
interest, Nlrp3-deﬁcient mice exhibited delayed demyelination
and oligodendrocyte depletion in a cuprizone-induced
demyelination model18. In the present study, we used
microarray analysis and identiﬁed 25-hydroxycholesterol (25-
HC) as a potent mediator in the pathogenesis of X-ALD. Our data
suggest that 25-HC, but not VLCFA, contributes to the cerebral
inﬂammation of X-ALD via activation of the NLRP3
inﬂammasome pathway.
Results
CH25H upregulation in CCALD patient-derived cells. To
recapitulate the distinctive features of X-ALD phenotypes, we
have previously generated induced pluripotent stem cells (iPSCs)
from the ﬁbroblasts of healthy control and X-ALD patients
including those with CCALD and AMN19. In early passage
cultures of iPSCs, VLCFA levels were signiﬁcantly higher in
CCALD-iPSCs compared with control iPSCs, AMN-iPSCs or
human embryonic stem cells (hESCs) (Supplementary Fig. 1).
To gain molecular insight into the inﬂammatory phenotype
of CCALD, we performed microarray-based transcriptional
proﬁling analysis of hESCs, control-, AMN- and CCALD-
iPSCs. We then identiﬁed 40 up- and 30 downregulated
genes in the CCALD-iPSCs compared with control iPSCs
(Supplementary Fig. 2). Among the 40 signiﬁcantly upregulated
genes, the expression level of nine genes was positively
correlated with phenotypic severity in the following order
(controloAMNoCCALD) (Fig. 1a). We also selected ﬁve
candidate genes from 40 up- and 30 downregulated genes based
on functional categorization of lipid metabolic processes for their
potential implication in VLCFA accumulation. Venn diagram
analysis indicated that CH25H (cholesterol 25-hydroxylase) and
CAT (catalase) were simultaneously relevant to the phenotypic
severity and lipid metabolism categories (Fig. 1b). CH25H
is a hydroxylating enzyme that converts cholesterol to
25-hydroxycholesterol (25-HC)20, whereas CAT is a well-known
antioxidant enzyme that catalyses the decomposition of hydrogen
peroxide21. Given that oxysterols such as 25-HC are involved in
the regulation of inﬂammation and also positively implicated in the
pathogenesis of inﬂammatory or neurodegenerative diseases22–24,
CH25H was then selected and examined for its potential role in the
cerebral inﬂammatory phenotype of X-ALD.
In addition to CH25H, CYP46A1 (also known as cholesterol
24-hydroxylase) and CYP27A1 are other major oxysterol-
producing enzymes that produce 24-HC and 27-HC,
respectively22. However, the expression of CYP46A1 or
CYP27A1 was not signiﬁcantly altered in CCALD-iPSCs
according to microarray analysis (Supplementary Table 1).
Increased mRNA expression of CH25H was also validated in
the CCALD-iPSCs by quantitative real-time PCR analysis, while
the expression of CYP46A1 and CYP27A1 was similar in all three
cell types (Fig. 1c).
To further validate the increased expression of CH25H of
CCALD patients-derived cells, we compared the levels of CH25H
in the ex vivo primary ﬁbroblasts of healthy control, AMN
patients and CCALD patients. Consistent with the expression
pattern of iPSCs, all three CCALD patients’ ﬁbroblasts showed a
signiﬁcant increase in CH25H mRNA expression compared with
control ﬁbroblasts (Fig. 1d). In addition, signiﬁcant upregulation
of CH25H mRNA was observed in one AMN ﬁbroblast, but not
in two other AMN ﬁbroblasts (Fig. 1d). Similarly, the level of
25-HC, a product of CH25H, also was signiﬁcantly increased in
the culture supernatants of all CCALD ﬁbroblast cultures
compared with control ﬁbroblast cultures (Fig. 1e). To conﬁrm
the potential relevance of this ﬁnding in oligodendrocytes, which
is the cell type primarily affected in the demyelination process of
X-ALD, we generated oligodendrocyte precursor cells (CCALD-
OPCs) differentiated from CCALD-iPSCs (Supplementary Fig. 3).
Consistent with the above observations, CH25H mRNA levels
were signiﬁcantly higher in CCALD-OPCs than control- or
AMN-OPCs (Fig. 1f). These ﬁndings strongly demonstrate
that the expression of CH25H is signiﬁcantly upregulated in
CCALD-derived cells.
ABCD1-dependent regulation of CH25H mRNA expression.
To determine whether a defect in function of ABCD1 was
involved in the induction of CH25H mRNA expression, we
reduced ABCD1 expression in control ﬁbroblasts by siRNA-
mediated knockdown (Supplementary Fig. 4a). Knockdown of
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ABCD1 caused a signiﬁcant increase in VLCFA levels and CH25H
mRNA expression (Fig. 2a,b). Of note, CCALD-ﬁbroblasts
showed much higher levels of VLCFA and of CH25H mRNA
than ABCD1-knockdowned ﬁbroblasts (Fig. 2a,b). Conversely,
ectopic expression of ABCD1 in CCALD-ﬁbroblasts signiﬁcantly
attenuated the level of VLCFA and CH25H mRNA
(Supplementary Fig. 4b and Fig. 2c,d). These ﬁndings indicate
that the dysfunction of ABCD1 observed in X-ALD patients
contributes to the induction of CH25H expression. Supporting
these observations, increased Ch25h expression was also found in
the brain homogenates of Abcd1-deﬁcient mice compared
with wild-type mice, while the expression of other cholesterol-
metabolizing enzymes was unchanged (Fig. 2e).
Next, we examined whether VLCFA accumulation triggered by
ABCD1 dysfunction directly mediated the induction of CH25H
expression. Exogenous addition of VLCFA did not affect the
expression of CH25H in control ﬁbroblasts, possibly due to the
presence of a fully functional ABCD1, but led to signiﬁcantly
increased CH25H mRNA levels in CCALD-ﬁbroblasts (Fig. 2f).
Similarly, VLCFA treatment also led to increased expression of
CH25H in CCALD-OPCs (Fig. 2g). These observations demon-
strate that the accumulation of VLCFAs resulting from a defective
ABCD1 gene may account for the induction of CH25H expression
in CCALD-derived cells.
Microglial recruitment and IL-1b production by 25-HC.
Recently, much attention has been paid to oxysterols, including
25-HC, as a potential regulator of innate or adaptive immune
responses23–25. Given that neuroinﬂammation is closely related to
the pathogenesis of CCALD7, we examined whether the elevated
level of 25-HC could mediate cerebral inﬂammation. Therefore,
we stereotactically injected 25-HC into the corpus callosum of
wild-type mouse brains (Fig. 3a), and measured the recruitment
of microglia, a major cell type for inducing neuroinﬂammation.
To our surprise, signiﬁcant recruitment of Iba-1-positive
microglia was observed around the 25-HC-injected region, but
not around the contralateral vehicle-injected region (Fig. 3b,c).
Then, we examined whether 25-HC could mediate pro-
inﬂammatory responses. Considering that pro-inﬂammatory
cytokines such as TNF-a, IL-1b and IFN-g were increased
in the demyelination plaques of X-ALD brains3,26, these
pro-inﬂammatory cytokines were measured in mouse brain
homogenates. Among the tested cytokines, only IL-1b
production was signiﬁcantly increased in the 25-HC-injected
hemisphere compared with the contralateral control region
(Fig. 3d), whereas the levels of other pro-inﬂammatory
cytokines such as TNF-a, IFN-g, IL-6 and MCP-1 were
unchanged in the two regions (Supplementary Fig. 5).
IL-1b is a key inﬂammatory cytokine that triggers
pro-inﬂammatory responses at the site of inﬂamed tissues27.
Unlike other cytokines, the production of functional IL-1b
requires the additional post-translational regulator, caspase-1
(ref. 28). Thus, to validate whether the elevated level of IL-1b
in the 25-HC-injected region resulted from the potentiated
activation of caspase-1, we examined the presence of active
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Figure 1 | CH25H is upregulated in CCALD patient-derived cells. (a) Candidate genes signiﬁcantly up- or downregulated (fold-change cutoff Z2 and
Po0.05) were selected based on the microarray analysis of human ESCs, control-, AMN- and CCALD-iPSCs. Heat map of nine selected genes showing the
expression patterns correlated with disease severity via microarray analysis. (b) Venn diagram of overlapping genes between nine genes related to disease
severity and ﬁve genes (among 70 genes) related to lipid metabolism. Catalase (CAT) and CH25H belong to both categories. (c) Relative mRNA expression
of three cholesterol-hydroxylating enzymes in the control- and AMN- or CCALD-iPSCs measured by quantitative real-time PCR analysis. (n¼6)
(d,e) Levels of CH25H mRNA in the cell lysates (d) and of 25-HC in the culture supernatants (e) of control- (human dermal ﬁbroblast), 3 AMN- and
3 CCALD-ﬁbroblasts. (d, n¼6; e, n¼4) (f) Relative mRNA expression of CH25H in the control- or X-ALD-iPSC-derived oligodendrocyte precursor cells
(AMN- or CCALD-OPCs). (n¼6) For all panels, *Po0.05, **Po0.01 and ***Po0.001.
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caspase-1 in the corpus callosum of mouse brain using an active
caspase-1-speciﬁc ﬂuorochrome-labeled inhibitors of caspases
(FLICA) probe, which yields green ﬂuorescence in active-caspase-
1-containing cells. Active caspase-1 was evident only in the
microglia in the 25-HC-injected region (Fig. 3e), which indicated
that the elevated IL-1b reﬂected the robust activation of caspase-
1. Furthermore, an amoeboid morphology of the activated
microglia was observed around the 25-HC-injected regions
(Fig. 3e, lower right).
To further conﬁrm whether 25-HC could trigger the
production of IL-1b in cell culture, we examined the potential
effect of 25-HC and VLCFA in mouse bone marrow-derived
macrophages (BMDMs). Intriguingly, 25-HC, but not VLCFA, in
the presence of lipopolysaccharide (LPS) co-treatment caused a
marked secretion of IL-1b in BMDMs (Fig. 3f), whereas neither
25-HC nor VLCFA affected the LPS-stimulated secretion of IL-6
(Fig. 3g). However, 25-HC treatment did not induce mRNA
expression of lL-1b and IL-6 in BMDMs (Supplementary
Fig. 6a,b). These observations suggest that 25-HC, but not
VLCFA, could activate the production of IL-1b in a transcription-
independent manner.
NLRP3 inﬂammasome assembly and activation by 25-HC.
Activation of caspase-1 requires the assembly and activation of
the inﬂammasome complex15. This led us to investigate whether
heightened 25-HC production could activate inﬂammasome
signalling. Consistent with the above results, 25-HC treatment
promoted a robust processing of caspase-1 and secretion of active
IL-1b in mouse BMDMs and microglia in the presence of LPS
co-treatment (Fig. 4a). This 25-HC-triggered activation of
caspase-1 and IL-1b was also found in mouse primary mixed
glial cells and human THP-1 macrophages (Supplementary
Fig. 7a,b). In contrast, VLCFA did not activate caspase-1
signalling in BMDMs (Fig. 4b), mixed glial cells, or THP-1 cells
(Supplementary Fig. 8a,b), which demonstrated that caspase-1-
activating capability was speciﬁc to 25-HC, but not to VLCFA.
In particular, the microglia-enriched population exhibited a
stronger activation of caspase-1 signalling than mixed glial cells
containing o10% microglia (Supplementary Fig. 9a,b). Indeed,
the expression of the major inﬂammasome components,
apoptosis-associated speck-like protein containing a caspase-
recruitment domain (ASC) and NLRP3, were increased in the
microglia relative to mixed glial cells (Supplementary Fig. 9b).
These data suggest that microglia might be the primary cell
population that activates caspase-1 when 25-HC accumulates in
the brain.
To provide molecular insight into the inﬂammasome activation
by 25-HC, we next investigated ASC oligomerization, which is a
critical step in inﬂammasome activation29. Consistent with the
above data showing the secretion of active caspase-1 and IL-1b,
25-HC promoted a robust oligomerization of ASC as determined
by a discuccinimidyl suberate (DSS)-crosslinking assay (Fig. 4c).
Among the identiﬁed inﬂammasomes, NLRP3 shows the unique
features of recognizing diverse endogenous danger signals such as
palmitic acid16,30. To investigate the possibility that 25-HC
could activate the NLRP3 inﬂammasome, we examined the
oligomerization of NLRP3 using NLRP3-GFP-expressing
macrophages. Noticeably, 25-HC treatment caused formation of
speck-like aggregates of NLRP3 (Fig. 4d), indicating that 25-HC
might act as another endogenous danger signal for NLRP3
activation. To further validate whether 25-HC could trigger the
assembly of NLRP3 inﬂammasome, the spatial proximity of
NLRP3 with ASC was measured using a proximity-ligation assay
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as recently described31. Consistent with the oligomerization of
ASC and NLRP3, 25-HC treatment caused a marked increase in
the proximity-ligation signal, which represented the molecular
assembly of NLRP3 with ASC (Fig. 4e and Supplementary
Fig. 10).
Supporting these observations, 25-HC-promoted caspase-1
processing and IL-1b secretion were completely abolished in
Nlrp3-deﬁcient BMDMs (Fig. 4f), microglia and mixed glial cells
(Supplementary Fig. 11a,b). Conversely, the restoration of NLRP3
expression in Nlrp3 / immortalized BMDMs regained the
susceptibility to 25-HC-induced caspase-1 activation (Fig. 4g). In
correlation with these ﬁndings, 25-HC-triggered IL-1b secretion
was largely impaired in Nlrp3-lacking microglia (Fig. 4h) and
BMDMs (Supplementary Fig. 11c), while LPS-triggered IL-6
secretion was not affected by the absence of NLRP3 in either cell
type (Fig. 4i and Supplementary Fig. 11d). These data strongly
demonstrate that 25-HC is a potent inducer of the NLRP3
inﬂammasome assembly and activation.
Molecular mechanism of NLRP3 activation by 25-HC. Despite
the fact that diverse stimulators have been shown to activate
NLRP3 inﬂammasomes, the detailed molecular mechanism of
how NLRP3 is activated is not fully understood. To provide
molecular insight into the NLRP3 activation by 25-HC, we ﬁrst
examined its dependence on potassium (Kþ ) efﬂux, currently
regarded as the most common mediator of NLRP3 activation in
response to diverse stimulators32. The inhibition of Kþ efﬂux by
glibenclamide or high extracellular KCl markedly attenuated
25-HC-induced caspase-1 and IL-1b processing in mouse
BMDMs (Fig. 5a). Consistently, glibenclamide also blocked the
oligomerization of ASC (Fig. 5b) and the association of NLRP3
and ASC (Fig. 5c and Supplementary Fig. 12) in mouse BMDMs
in response to 25-HC treatment. These ﬁndings indicate that Kþ
efﬂux is involved in the 25-HC-triggered activation of NLRP3
inﬂammasome.
In addition to Kþ efﬂux, mitochondrial damage or mitochon-
drial ROS (mtROS) production is also considered a crucial
mediator of NLRP3 activation in response to diverse NLRP3
agonists16,33. Interestingly, 25-HC treatment induced a
considerable increase in mtROS-producing cells as measured
using a mtROS-speciﬁc MitoSOX probe in BMDMs (Fig. 5d,
upper panel). To provide more evidence that 25-HC could impair
the function of mitochondria, we determined another indication
of mitochondrial damage by co-staining with MitoTracker
Green and MitoTracker Deep Red to measure the dissipation of
mitochondrial membrane potential33–35. Consistent with mtROS
production, treatment with 25-HC caused an obvious increase in
the damaged mitochondria-containing cell population (Fig. 5d,
lower panel). This increase in mtROS-producing or damaged
mitochondria-containing cells was also observed in the Nlrp3-
deﬁcient BMDMs upon 25-HC stimulation (Supplementary
Fig. 13a,b), indicating that these mitochondrial alterations
by 25-HC were not consequences of caspase-1/inﬂammasome
activation. Similarly, 25-HC treatment resulted in the production
of mtROS in microglia (Supplementary Fig. 13a, lower panel).
These observations indicate that 25-HC treatment could impair
mitochondria in an inﬂammasome activity-independent manner.
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Additionally, N-acetyl-cysteine (NAC), a general antioxidant,
and Mito-TEMPO, a mitochondria-speciﬁc ROS scavenger, led to
a marked reduction in caspase-1 activation (Fig. 5e) and ASC
oligomerization (Fig. 5f) in BMDMs stimulated with 25-HC. As
expected, Mito-TEMPO considerably attenuated the increase in
mtROS-producing BMDMs (Supplementary Fig. 14a), suggesting
that mtROS production might be related to the underlying
mechanism of NLRP3 inﬂammasome actiation by 25-HC. Of
note, the 25-HC-induced mitochondrial alterations were not an
immediate, but rather a delayed phenomenon that was observed
after at least 3 h of 25-HC treatment (Supplementary Fig. 14b). In
correlation with this ﬁnding, 25-HC-induced caspase-1 activation
was observed only after at least 6 h of 25-HC treatment
(Supplementary Fig. 15a,b). On the basis of these data, we
inferred that 25-HC caused the mitochondrial damage in the
delayed response, which was likely associated with the NLRP3
activation by 25-HC.
A recent report showed that liver X receptor (LXR) ligands,
such as TO901317 or 25-HC, promoted the caspase-1-dependent
cell death of colon cancer cells36. Furthermore, the authors
proposed that LXR ligands could induce the activation of NLRP3
inﬂammasome possibly through inducing the extracellular
secretion of ATP36. Therefore, we examined the involvement of
LXR signalling in the 25-HC-triggered activation of NLRP3 using
a LXR antagonist, 22(S)-hydroxycholesterol (22(S)-HC). Co-
treatment with 22(S)-HC showed a remarkable reduction of
caspase-1 and IL-1b secretion in mouse BMDMs stimulated with
25-HC (Fig. 5g). However, 22(S)-HC did not abolish the ATP-
stimulated canonical NLRP3 inﬂammasome activation (Fig. 5h).
Consistently, 22(S)-HC also blocked the 25-HC-induced
oligomerization of ASC (Fig. 5i). These data suggest that LXR
signalling might be mediated in the 25-HC-triggered activation of
NLRP3. In agreement with a recent report36, TO901317, another
synthetic LXR agonist, exhibited the potent capability to activate
caspase-1 (Supplementary Fig. 16a). Unlike 25-HC, TO901317-
induced caspase-1 activation was observed in Nlrp3 /
BMDMs (Supplementary Fig. 16a) and was not inhibited by the
potassium efﬂux blocker glibenclamide (Supplementary Fig. 16b).
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These observations demonstrate that TO901317 could promote
caspase-1 activation in an NLRP3-independent manner.
Furthermore, TO901317 exhibited much higher toxicity to
BMDMs compared with 25-HC (Supplementary Fig. 16c). On
the basis of these ﬁndings, LXR signalling was potentially
involved in NLRP3 inﬂammasome activation at least in the case
of 25-HC stimulation. Supporting our data, the 25-HC-induced
secretion of IL-1b was effectively suppressed by the Kþ efﬂux
blocker, the mtROS scavenger and the LXR antagonist
(Supplementary Fig. 17).
NLRP3 deﬁciency reduces cerebral inﬂammation by 25-HC.
To validate the contribution of the NLRP3 inﬂammasome to
25-HC-induced cerebral inﬂammation, we measured the
recruitment of microglia after the stereotaxic injection of 25-HC
into the corpus callosum of Nlrp3þ /þ and Nlrp3 / mice.
Recruitment of microglia into the 25-HC-injected region was
signiﬁcantly reduced in Nlrp3-deﬁcient mice (Fig. 6a,b).
Moreover, 25-HC-induced production of IL-1b was signiﬁcantly
attenuated in the brain of Nlrp3 / mice (Fig. 6c). To
further support these data, we used a recombinant IL-1
receptor antagonist (IL-1Ra) to conﬁrm whether microglial
recruitment was inﬂammasome-dependent in our experiments.
25-HC-triggered recruitment of microglia was signiﬁcantly
reduced by the administration of the IL-1Ra (Fig. 6d,e), which
indicated that IL-1b played a crucial role in the recruitment of
microglia into the 25-HC-injected area.
Oligodendrocytes are the major myelin-forming cells of the
central nervous system. 25-HC injection caused robust apoptotic
cell death of oligodendrocytes in the 25-HC-injected region, but
not in the vehicle-injected contralateral region (Fig. 6f). This
ﬁnding suggested that the increased level of 25-HC was indeed
responsible for the depletion of oligodendrocytes; it is possible
that oligodendrocyte depletion could lead to the demyelination
observed in X-ALD. To our surprise, this 25-HC-induced loss of
oligodendrocytes were signiﬁcantly attenuated in Nlrp3 / mice
(Fig. 6g,h). These ﬁndings clearly demonstrate that 25-HC could
cause oligodendrocytes apoptosis via activation of the NLRP3
inﬂammasome. In support of our data, Abcd1-deﬁcient mice
showed increased susceptibility to cerebral inﬂammations as
shown by oligodendrocyte apoptosis (Fig. 6i and Supplementary
Fig. 18a) and the recruitment of microglia (Supplementary
Fig. 18b,c) in response to the stereotaxic administration of
25-HC. Our data collectively demonstrate that 25-HC promoted
NLRP3 inﬂammasome assembly and activation that led to the
recruitment of microglia and apoptosis of oligodendrocytes.
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Discussion
The underlying mechanism by which cerebral inﬂammation is
initiated has been a long-standing conundrum in the pathogen-
esis of X-ALD7. VLCFA is considered the best biomarker of
X-ALD6, but its contribution to the neuroinﬂammation of
CCALD is still unclear10. In the present study, we identiﬁed the
unique upregulation of CH25H and the subsequent production of
25-HC in CCALD-derived cells. Indeed, accumulated VLCFA
was responsible for the induction of CH25H (Fig. 2f,g). CH25H
was previously suggested as a risk factor for the pathogenesis of
Alzheimer’s diseases37,38, which indicated that CH25H induction
and the subsequent production of 25-HC could contribute to the
progression of neurodegenerative diseases. In correlation with
this observation, our data showed that 25-HC could act as a
potent mediator and inducer of cerebral inﬂammation in CCALD
through its ability to activate the NLRP3 inﬂammasome.
25-HC was ﬁrst identiﬁed as a feedback suppressor of
cholesterol biosynthesis that acted mainly by inhibiting pathways
involved with sterol response element-binding proteins22.
CH25H is one of the highly inducible, interferon-stimulated
genes expressed in response to viral infection39. Its product,
25-HC, affects multiple steps of the viral life cycle including the
inhibition of viral entry, viral replication and particle
assembly23,39. However, the contribution of 25-HC to the
inﬂammatory response still remains to be further investigated,
particularly in terms of transcriptional control of pro-
inﬂammatory cytokine expressions. Previous literature reported
that 25-HC could augment the inﬂammatory response, leading to
increased secretion of pro-inﬂammatory cytokines, such as IL-1b
and IL-6 (refs 40–43). Recently, Gold et al. showed that Ch25h /
 mice were less susceptible to inﬂuenza A virus infection due to
a decreased inﬂammatory response, and proposed that 25-HC
could amplify the production of toll-like receptor (TLR)-induced
cytokines by facilitating AP-1-mediated transcription40.
Supporting the pro-inﬂammatory role of 25-HC, another study
demonstrated that 25-HC-triggered IL-1b production in
co-cultures of human monocytes and vascular smooth muscle
cells41. In correlation with its pro-inﬂammatory function,
25-HC has been considered to promote the progression of
chronic inﬂammatory diseases, including atherosclerosis, chronic
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(a) Immunohistochemical staining of coronal brain sections with anti-Iba-1 antibody (green) and DAPI (blue) after bilateral stereotaxic injection of
25-HC (100mM) or vehicle into the brain of Nlrp3þ /þ or Nlrp3 / mice. Scale bar, 200mm. (b) Quantiﬁcation of Iba-1þ microglia in confocal images
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(blue). Lower panel is representative magniﬁed image of a 25-HC-injected region. Arrows indicate the active caspase-3-positive oligodendrocytes (yellow).
Scale bars, 200mm (upper); 50mm (lower). (g) Immunohistochemical staining of brain sections of Nlrp3þ /þ or Nlrp3 / mice stained as in f after
stereotaxic injection of vehicle or 25-HC. Scale bar, 100mm. (h) Quantiﬁcation of active caspase-3þ oligodendrocytes in the confocal images of vehicle-
or 25-HC-injected brain sections as treated in g. (n¼6) (i) Quantiﬁcation of active caspase-3þ oligodendrocytes in the confocal images of vehicle- or
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obstructive pulmonary disease, and Alzheimer’s disease37,44,45.
However, the precise role of 25-HC in inﬂammasome activation
at the molecular level has been poorly described to date.
By contrast, a recent paper demonstrated increased secretion of
IL-1b in Ch25h-deﬁcient BMDMs upon LPS-ATP stimulation,
and proposed that 25-HC could attenuate the production of
pro-IL-1b by inhibiting sterol response element-binding proteins-
mediated transcription46. We cannot fully explain these
discrepancies about the contribution of 25-HC to inﬂammation
at present. One possible explanation could be the different
concentration of 25-HC used. For example, more than
micromolar concentrations of 25-HC were employed in the
studies proposing its pro-inﬂammatory action40–43, whereas
nanomolar concentrations were used when documenting anti-
inﬂammatory effects46. The physiological concentration of 25-HC
in the brain is difﬁcult to measure, but the level of 25-HC might
possibly be elevated in the demyelinating plaque of CCALD due
to the increased VLCFA level47,48. With these conﬂicting reports,
we carefully examined the role of 25-HC in BMDMs, microglia,
and human THP-1 cells, as well as in the mouse brain, and we
provide deﬁnitive molecular evidences to support the pro-
inﬂammatory role of 25-HC in NLRP3 inﬂammasome activation.
Like other classical NLRP3 agonists, 25-HC also induced a
potassium efﬂux-dependent NLRP3 inﬂammasome activation.
Emerging evidence has proposed a potential linkage between
mitochondrial damage or damaged mitochondria-derived
danger signals such as mtROS and activation of the NLRP3
inﬂammasome under diverse stress conditions33,49. Of note,
25-HC caused robust production of mtROS and mitochondrial
damage, which was consistent with the previous report50. The
scavenging of mtROS markedly attenuated 25-HC-induced
caspase-1 activation and ASC oligomerization under our
experimental conditions. Despite the poor understanding of
how 25-HC causes mitochondrial dysfunction, mitochondrial
damage and mtROS were shown to be closely related to the
pathogenesis of ALD51–53. In this regard, it is plausible that
mtROS production is involved in 25-HC-induced NLRP3
inﬂammasome activation that could possibly result in the
pathophysiology of CCALD. In addition, our data showed that
25-HC alone without LPS co-treatment could activate NLRP3
inﬂammasome in BMDMs and microglia, but failed to induce
IL-1b mRNA expression. Considering that NLRP3
inﬂammasome activation requires a priming step, it is
questionable as to whether 25-HC could provide a priming
signal for NLRP3 activation in the physiological context. Of
interest, 25-HC alone promoted NLRP3-independent cell death
of BMDMs and mixed glial cells (Supplementary Fig. 19), which
suggested that 25-HC-triggered cell death could release a danger
signal that functions as a priming signal under physiological
conditions.
Given that 25-HC is a potent ligand of the LXR pathways25,
we also investigated the involvement of LXR signalling in
25-HC-triggered NLRP3 inﬂammasome activation. A recent
report consistently demonstrated that LXR ligands could
promote the activation of NLRP3 inﬂammasome in colon
cancer cells leading to cell death36. In our study, LXR signalling
was likely to be involved in the 25-HC-induced caspase-1
activation of BMDMs. However, whether the engagement of
LXR is a potent stimulator of NLRP3 remains to be elucidated.
Another LXR agonist, TO901317, showed potent caspase-1
activation in BMDMs, as well as in Nlrp3-deﬁcient cells. In this
regard, further study will be required to address the precise role of
the LXR pathways in inﬂammasome signalling.
The potential contribution of the NLRP3 inﬂammasome
to chronic inﬂammatory disorders has been increasingly
demonstrated54. In correlation with our study, the NLRP3
inﬂammasome was already shown to play a crucial role in
demyelination and oligodendrocyte loss in a mouse model18,
which suggested the signiﬁcance of the NLRP3 inﬂammasome in
cerebral neuroinﬂammation. Interestingly, endogenous molecules
such as palmitate, uric acid crystals, cholesterol crystals and
amyloid b, which are critical in the pathogenesis of chronic
metabolic or neurodegenerative disorders, have been shown
to activate the NLRP3 inﬂammasome13,54. Here, we present
evidence that 25-HC could act as an endogenous NLRP3
stimulator leading to cerebral inﬂammation. Therefore, our data
suggest that therapeutic interventions that can target the NLRP3
inﬂammasomes may show clinical beneﬁt for the treatment of
X-ALD.
Methods
Mice. C57BL/6, Abcd1þ / , and Nlrp3 / mice were obtained from The Jackson
Laboratory and bred at Yonsei University College of medicine. All mice were on
C57BL/6 background and 7–10 weeks male mice were used for the experiments. All
mice were maintained under speciﬁc pathogen-free conditions. Protocols for the
animal experiments were approved by the Institutional Ethical Committee, Yonsei
University College of Medicine. All experiments were performed in accordance
with the approved guidelines of the Institutional Ethical Committee.
Establishment of X-ALD patients-derived cells. hESC and human iPSCs were
maintained as described previously19. Human X-ALD-ﬁbroblasts (GM04496
(CCALD1), GM04934 (CCALD 3), GM04932 (CCALD4), GM07675 (AMN 2),
GM17819 (AMN3)) and control human dermal ﬁbroblast (HDF, C-004-5C) cells
were purchased from Coriell Institute and Invitrogen, respectively. Human
ﬁbroblasts were cultured as recommended by the manufacturer. Human
X-ALD-ﬁbroblasts were also derived and established from skin punch biopsies
taken from a Korean CCALD patient (CCALD 2) and Korean AMN patient
(AMN 1). The patients’ clinical information is listed in the Supplementary Table 2.
Human iPSCs were established from control- (HDF), AMN3- and CCALD1-
ﬁbroblasts. Differentiation of oligodendrocytes was performed as described
previously19 and determined using anti-NG2 (Chemicon) and anti-A2B5
(Millipore) antibodies by ﬂow cytometry.
Ethical statement. Yonsei University Institutional Review Board approval
(IRB 4-2016-0194) was obtained for the generation and analyses of ﬁbroblasts from
adrenoleukodystrophy patients. All volunteers who participated in this study
signed written informed consent forms before skin biopsy sampling for human
ﬁbroblast establishment.
Cell cultures. Mouse bone marrow cells were isolated from mouse femurs and
differentiated into BMDMs with L929-conditioned medium55. Immortalized
NLRP3-reconstituted BMDMs (N1-8) and NLRP3-GFP-expressing BMDMs were
provided by E.S. Alnemri (Thomas Jefferson University, Philadelphia, PA, USA).
All BMDMs were maintained in L929-conditioned DMEM supplemented with
10% FBS and antibiotics. THP-1 cells were differentiated into macrophage-like cells
using a phorbol 12-myristate 13-acetate treatment and cultured in RPMI-1640
supplemented with 10% FBS, 2mM glutamine, 10mM HEPES, 1mM sodium
pyruvate, 0.05mM 2-mercaptoethanol and antibiotics56. Mouse brain mixed glial
cells were isolated from the whole brain of pups on the ﬁrst postnatal day and
cultured in DMEM/F-12 medium for 3 weeks as described previously57. Microglial
cells were further enriched from the mixed glial cultures by mild trypsinization58.
The microglia cultures were characterized by ﬂow cytometry after co-staining with
anti-CD11b and anti-F4/80 antibodies (eBioscience). Cell death was measured
by the extracellular release of lactate dehydrogenase (LDH) using a CytoTox96
non-radioactive cytotoxicity assay kit (Promega).
Microarray analysis. Microarray analysis was performed by Macrogen Inc.
Brieﬂy, 200 ng of total RNA from puriﬁed hESCs (P35–45), control iPSCs
(P10–20), CCALD-iPSCs (P10–20), AMN-iPSCs (P10–20) was transcribed to yield
biotinylated complementary RNA according to the manufacturer’s instructions.
Complementary RNA samples were each hybridized to a Human HT-12 v4.0
Expression Beadchip (Illumina). Arrays were scanned with an Illumina Bead Array
Reader confocal scanner according to the manufacturer’s instructions. Raw data
were processed using the Illumina GenomeStudio v2011.1 (Gene Expression
Module v1.9.0)). Gene-enrichment and functional annotation analysis for the
signiﬁcant probe list was performed using Gene Ontology (www.geneontology.org/).
All data analysis and visualization of differentially expressed genes was
conducted using R 3.1.2 (www.r-project.org). Microarray data have been deposited
in the Gene Expression Omnibus database (GSE85804).
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Measurement of VLCFA and 25-HC. VLCFAs were measured as fatty acid methyl
esters as described previously19. Brieﬂy, after adding C27:0 as the internal standard,
total lipid were extracted, converted to methyl esters, puriﬁed by thin-layer
chromatography, and subjected to gas chromatography (GC). The level of 25-HC
in culture media was determined by GC coupled with mass spectrometry (GC-MS)
as described previously59. A deuterium-labelled internal standard (D6-25-HC) was
used for calculating the concentration of 25-HC.
ABCD1 expression. To knockdown ABCD1 expression, cells were transfected
with scrambled siRNA (4390843, Ambion) or ABCD1-targeting siRNAs (s1233,
Invitrogen, 50-CCUUCACUAUUGCCCGCAAtt-30 ; 50-UUGCGGGCAAUAGUG
AAGGct-30) using Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s instructions. To induce ectopic expression of ABCD1, cells were
infected with lentiviral particles expressing vector or ABCD1. Lentiviral particles
were prepared from the supernatants of 293GPG packaging cells transfected with
empty or ABCD1-expressing lentiviral construct (Addgene).
Quantiﬁcation of mRNA. To measure mRNA production, total RNA was isolated
using RNeasy Mini Kit (Intron) or Trizol reagent (Invitrogen) and reverse
transcribed using Power cDNA synthesis kit (Intron). Quantitative real-time PCR
were performed using SYBR Premix Ex Taq (Takara). Primers were as follows:
(human CYP46A1) 50-TGTGTTTTTGGATTG GGCTAAGA-30 and 50-ACTCAG
GACTCGTGACGATGA-30 ; (human CH25H) 50-GCACTGCCTGCCAAGCG
AGA-30 and 50-CTCCGCAGACAGCTCCCCCT-30 ; (human CYP27A1) 50-CGG
CAACGGAGCTTAGAGG-30 and 50-GGCATAGCCTTGAACGAACAG-30 ;
(mouse Cyp46a1) 50-GGACATCTCCCCTACTTTTGGA-30 and 50-GGACCATAC
TTCTTAGCCCAATC-30; (mouse Ch25h) 50-ATGGGCTGCTACAACGGTTC-30
and 50-CCTTGTCCTTATGGTGTCCCAG-30; (mouse Cyp27a1) 50-GCACAGG
AGAGTACGGAGG-30 and 50-CGGGCAAGTGCAGCACATA-30 . Relative
expression was expressed as means ± s.e.m. obtained from three independent
experiments.
Stereotaxic injection. Mice were anaesthetized with a mixture of tiletamine/
zolazepam (Zoletil) and xylazine (Rompun) and mounted in a stereotaxic frame
(Stoelting). The mice were injected with vehicle or 25-HC in the white matter of
the corpus callosum over both hemispheres (1 or  1mm lateral to the midline,
1mm anterior to Bregma and 2mm deep) via separate Hamilton syringes. In some
experiments, recombinant human IL-1Ra (5 mg, Prospec) was co-injected with
25-HC. After 3 days, mice were anaesthetized and were transcardially perfused
with paraformaldehyde. Brains were removed and were placed overnight at 4 C in
4% (vol/vol) paraformaldehyde, then transferred to PBS. Coronal sections of 20 mm
in thickness were prepared using a Vibratome microtome (Leica).
Immunohistochemistry. Cells were ﬁxed in 4% paraformaldehyde, permeabilized
and stained with the primary antibodies targeting MBP (Abcam, ab7349, 1:100),
cleaved caspase-3 (Cell Signaling Technology, 9661, 1:100) and Iba-1 (Wako,
019-19741, 1:100), followed by the appropriate Alexa Fluor 488- or 594-labelled
secondary antibodies (Molecular Probes). DAPI counterstaining was used for
nuclei visualization. Cell images were captured with an Olympus IX71 microscope
and DP71 digital camera or Olympus FSX100 system. Iba-1-positive cells in the
selected regions were counted using Image J.
Immunoblot analysis. Cells were lysed in buffer containing 20mM HEPES
(pH 7.5), 0.5% Nonidet P-40, 50mM KCl, 150mM NaCl, 1.5mM MgCl2,
1mM EGTA and protease inhibitors. Soluble lysates were fractionated by
SDS–polyacrylamide gel electrophoresis and then transferred to polyvinylidene
diﬂuoride membranes. In some experiments, cell culture supernatants were pre-
cipitated by the addition of methanol/chloroform mixture as described previously60
and then immunoblotted. The following antibodies were used for detecting mouse
caspase-1 (Adipogen AG-20B-0042, 1:2,000), mouse IL-1b (R&D AF-401-NA,
1:1,000), human caspase-1 (Santa Cruz SC-515, 1:500), human IL-1b (Cell
Signaling 2022, 1:1,000), mouse NLRP3 (Adipogen AG-20B-0014, 1:2,000) and
mouse ASC (Santa Cruz SC-22514-R, 1:500). All the blots shown are representative
image of at least three independent experiments. Images have been cropped for
presentation. Full size images are presented in Supplementary Fig. 20.
Cytokine production assay. The levels of IL-1b or IL-6 in the culture
supernatants or the mouse brain homogenates were quantiﬁed by mouse IL-1b or
IL-6 ELISA (R&D). For the brain homogenates, inﬂammatory cytokines were also
quantiﬁed using the Cytometric Bead Array (CBA) Mouse Inﬂammatory Kit (BD).
All the assay experiments were performed according to the manufacturer’s
protocols.
Assay of inﬂammasome/caspase-1 activation. To induce a conventional
NLRP3 inﬂammasome activation, BMDMs or microglial cells were primed with
LPS (0.25 mgml 1, 3 h), followed with ATP treatment (2B2.5mM, 45min).
To measure the inﬂammasome-activating role of 25-HC or VLCFA, cells were
treated with 25-HC (1B100mM) or VLCFA (up to 100mM) for 10 h in the
presence of LPS treatment (0.25 mgml 1, last 4 h). In some experiments, cells were
ﬁrst primed with LPS (0.25mgml 1, 3 h), washed with PBS, and then treated with
25-HC or other agonists as indicated. Inﬂammasome activation was determined by
the presence of active caspase-1 p20 (mouse BMDM) or p10 (human THP-1 cells),
and active IL-1b from culture supernatants in immunoblots, and by the
extracellular IL-1b quantiﬁcation using ELISA. FAM-FLICA-caspase-1 assay kit
(ImmunoChemistry) was employed to detect active caspase-1 in the brain sections
according to the manufacturer’s protocol.
Assay of NLRP3 inﬂammasome assembly. To measure the oligomerization of
NLRP3, confocal microscopy of NLRP3-GFP-expressing BMDMs was performed
as described previously61. To quantify NLRP3 speck formation, the relative
percentage of NLRP speck-containing cells was determined by dividing the number
of NLRP3 speck-containing cells by the number of total cells. To determine the
oligomerization of ASC, DSS-mediated crosslinking assay was performed as
described previously62. To visualize the molecular interaction of NLRP3 with ASC,
proximity-ligation assay was performed using Duolink In Situ Red starter kit
(Sigma) using anti-ASC or anti-NLRP3 antibodies according to the manufacturer’s
protocols. The relative proximity-ligation signals (PL signals/DAPI signals) were
quantiﬁed using Image J and calculated as a relative fold-change compared with
untreated controls.
Measurement of mitochondrial ROS and damage. To measure mROS
production, cells were stained with MitoSOX (Invitrogen) according to the
manufacturer’s protocol and the ﬂuorescence of the cells was then monitored and
analysed by ﬂow cytometry (FACSVerse, BD). To assess mitochondrial membrane
potential-dependent damage, cells were co-stained with MitoTracker Deep Red and
MitoTracker Green (Invitrogen) according to the manufacturer’s protocol and
analysed by ﬂow cytometry. All ﬂow cytometry data are representative of at least
three independent experiments.
Statistical analysis. All values are expressed as the mean±s.e.m. of individual
samples or independent experiments. Data were analysed using the Student’s t test,
and P valuesr0.05 were considered signiﬁcant.
Data availability. Microarray data that support the ﬁndings of this study have
been deposited in the Gene Expression Omnibus (GEO) database with the
accession code GSE85804.
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